Komori
Revision of earnings forecasts2929Pharma Foods International Co.,Ltd.Food

Notice Regarding Revisions to the Full-Year Earnings Forecast for the Fiscal Year Ending July 2026

2026年7月期の通期連結予想を見直し、売上高は1,000百万円減額する一方、営業利益・経常利益・親会社株主に帰属する当期純利益はそれぞれ500百万円増額した。

Worth reading
69In focus
Scored from 4 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
500
¥ million
Wording
Conditional
How definitive the wording is.

Revised forecast

Fiscal year ending July 2026 · Full yearPrevious forecast published 11 September 2025
Net Sales68,000→67,000million
-1.5%
Operating profit1,500→2,000million
+33.3%
Ordinary income1,500→2,000million
+33.3%
Profit attributable to owners of the parent1,000→1,500million
+50.0%
Net income per share34.64→51.65yen and sen
+49.1%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

「ニューモシリーズ」の販売が堅調で、新製品の売上が伸長したことに加え、資本効率を重視したことで採算性が向上し、利益面で前回予想を上回る見通しとなった。

Previous-period results売上高 65,260百万円、営業利益 2,367百万円、経常利益 2,553百万円、親会社株主に帰属する当期純利益 368百万円、1株当たり当期純利益 12.83円 銭
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥68,000 million → ¥67,000 million(-1.5%)
Operating profit¥1,500 million → ¥2,000 million(+33.3%)
Ordinary income¥1,500 million → ¥2,000 million(+33.3%)
Profit attributable to owners of the parent¥1,000 million → ¥1,500 million(+50.0%)
Net income per share34.64 yen and sen → 51.65 yen and sen
Fiscal Period CoveredFiscal year ending July 2026
Period CoveredFull year
Publication date of previous forecast11 September 2025
Previous-period results売上高 65,260百万円、営業利益 2,367百万円、経常利益 2,553百万円、親会社株主に帰属する当期純利益 368百万円、1株当たり当期純利益 12.83円 銭
Reason for the revision「ニューモシリーズ」の販売が堅調で、新製品の売上が伸長したことに加え、資本効率を重視したことで採算性が向上し、利益面で前回予想を上回る見通しとなった。
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

BtoC事業で主力の「ニューモシリーズ」の販売が堅調だったほか、新製品の売上が伸長した。また、グループ全体で資本効率を重視した結果、採算性が向上し、利益が前回予想を上回る見通しとなった。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to the Full-Year Earnings Forecast for the Fiscal Year Ending July 2026 | Pharma Foods International Co.,Ltd. (2929) timely disclosure | Komori